Simple production of hydrophobin-fused domain III of dengue envelope protein and induction of neutralizing antibodies against the homotypic serotype of dengue virus

Cerezo, Julieta; Targovnik, Alexandra Marisa; Smith, María Emilia; Maglio, Daniel Horacio González; Luppo, Victoria; Morales, María Alejandra; Miranda, Magdalena; Talou, Julián Rodríguez

doi:10.1007/s10529-019-02767-2

Cited by 3 publications

(1 citation statement)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a lowcost strategy, the production of dengue antigens in wholeinsect larvae is possible. Within this context, Cerezo et al (2020) demonstrated that the DomIII from DENV-1 and DENV-2 fused to hydrophobin (DomIIIHFB) and produced in insect larvae could elicit serotype-specific neutralizing antibodies in mice without cross-reacting against heterologous serotypes and other flaviviruses. Therefore, the DomII-IHFB expression belonging to the four serotypes would be useful for providing reagents for the formulation of a lowcost tetravalent subunit vaccine (Cerezo et al 2020).…”

Section: Arboviruses Vaccines and Diagnostic-reagent Productionmentioning

confidence: 99%

Solutions against emerging infectious and noninfectious human diseases through the application of baculovirus technologies

Targovnik

Simonin

Callum

et al. 2021

Appl Microbiol Biotechnol

Self Cite

View full text Add to dashboard Cite

Baculoviruses are insect pathogens widely used as biotechnological tools in different fields of life sciences and technologies. The particular biology of these entities (biosafety viruses 1; large circular double-stranded DNA genomes, infective per se; generally of narrow host range on insect larvae; many of the latter being pests in agriculture) and the availability of molecular-biology procedures (e.g., genetic engineering to edit their genomes) and cellular resources (availability of cell lines that grow under in vitro culture conditions) have enabled the application of baculoviruses as active ingredients in pest control, as systems for the expression of recombinant proteins (Baculovirus Expression Vector Systems-BEVS) and as viral vectors for gene delivery in mammals or to display antigenic proteins (Baculoviruses applied on mammals-BacMam). Accordingly, BEVS and BacMam technologies have been introduced in academia because of their availability as commercial systems and ease of use and have also reached the human pharmaceutical industry, as incomparable tools in the development of biological products such as diagnostic kits, vaccines, protein therapies, and-though still in the conceptual stage involving animal models-gene therapies. Among all the baculovirus species, the Autographa californica multiple nucleopolyhedrovirus has been the most highly exploited in the above utilities for the human-biotechnology field. This review highlights the main achievements (in their different stages of development) of the use of BEVS and BacMam technologies for the generation of products for infectious and noninfectious human diseases. Key points• Baculoviruses can assist as biotechnological tools in human health problems.• Vaccines and diagnosis reagents produced in the baculovirus platform are described.• The use of recombinant baculovirus for gene therapy-based treatment is reviewed.

show abstract

Section: Arboviruses Vaccines and Diagnostic-reagent Productionmentioning

confidence: 99%